voxelotor

July 5, 2018July 5, 2018

First Results from Phase 3 Trial Expected to Support FDA’s Accelerated Approval of Voxelotor for Sickle Cell

News

Once-daily treatment with voxelotor, Global Blood Therapeutics’ lead therapy candidate, can effectively increase the amount of hemoglobin in about 58% of patients with sickle cell disease (SCD) in just 12 weeks, ... Read more

January 16, 2018

FDA Grants Breakthrough Therapy Designation to Voxelotor

News

Voxelotor, a potential treatment for sickle cell anemia (SCA), has been given breakthrough therapy designation (BTD), Global Blood Therapeutics (GBT) recently announced. Voxelotor (previously called GBT440) is a potential ... Read more

January 2, 2018

Voxelotor Improves Sickle Cell Disease of 83% of Adolescents in Phase 2a Trial

News

The sickle disease of 83 percent of adolescents improved after 16 weeks of taking Global Blood Therapeutics‘ voxelotor, preliminary results of a Phase 2a clinical trial indicate. Another important finding ... Read more

November 21, 2017

Review Board Finds Global Blood’s Sickle Cell Disease Therapy Voxelotor Is Safe

News

An independent review board has found Global Blood Therapeutics’ sickle cell disease treatment voxelotor safe, and recommended that its Phase 3 clinical trial continue. The hallmark of sickle cell disease is damage to ... Read more

November 14, 2017November 14, 2017

Sickle Cell Patient with Severe Anemia Rapidly Improves with Voxelotor, Case Study Shows

News

Global Blood Therapeutics (GBT) reported a case study in which a sickle cell disease (SCD) patient was granted compassionate access to the company’s ongoing Phase 3 HOPE study of voxelotor ... Read more

Pin It on Pinterest